Metoclopramide Hydrochloride Syri (Metoclopramide Hydrochloride)

The drug blocks dopamine D2 receptors in the chemoreceptor trigger zone, reducing nausea signals to the brain. Simultaneously, it increases acetylcholine release in the gut, stimulating smooth‑muscle contractions that accelerate gastric emptying and improve overall digestive motility.

Dosing is individualized and set by the prescribing clinician based on the patient’s condition, age, renal function, and response. Typical regimens vary, and the prescriber will determine the appropriate strength, frequency, and duration for each case.

Safety data for Metoclopramide in pregnancy are limited and the pregnancy category is unknown. It should only be used when the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Metoclopramide differs from agents like ondansetron, which target serotonin receptors, and domperidone, which also blocks peripheral dopamine receptors but has limited central nervous system penetration. Metoclopramide provides both anti‑nausea and pro‑kinetic effects, making it useful for conditions where enhanced gastric motility is desired, though it carries a higher risk of extrapyramidal symptoms.

Store the product at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not refrigerate or freeze the tablets. Keep out of reach of children and ensure the container is tightly closed when not in use.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, although taking it with a meal can reduce gastrointestinal irritation. The exact administration schedule is determined by the prescribing clinician.

Serious adverse reactions include tardive dyskinesia, a potentially irreversible movement disorder, and neuroleptic malignant syndrome, a life‑threatening condition characterized by fever, muscle rigidity, and autonomic instability. Other critical risks are severe depression, seizures, and allergic reactions such as anaphylaxis.

Contraindications include known hypersensitivity to metoclopramide or any component of the formulation, patients with pheochromocytoma, and those with mechanical gastrointestinal obstruction. Caution is also advised in individuals with severe renal impairment, epilepsy, or a history of extrapyramidal disorders.